B. Pascual-sedano et al., Prospective study of new-onset seizures in patients with human immunodeficiency virus infection - Etiologic and clinical aspects, ARCH NEUROL, 56(5), 1999, pp. 609-612
Objective: To determine the frequency and etiologic and clinical aspects of
new-onset seizures in patients with human immunodeficiency virus (HIV) inf
ection.
Design: A prospective survey of an HIV-infected patient cohort.
Setting: Outpatients and inpatients in a university hospital in Barcelona,
Spain.
Patients: Five hundred fifty HIV-infected patients recruited over 1 year.
Main Outcome Measure: Analysis of new-onset seizures, with detailed medical
history and appropriate workup.
Results: Seventeen HIV-infected patients (3%) had a new-onset seizure durin
g the study period. Fourteen (82%) of 17 patients had acquired immunodefici
ency syndrome diagnosed according to the 1993 CDC Expanded AIDS Definition.
Mean latency (+/- SD) between diagnosis of HIV infection and the first sei
zure was 60.7 +/- 37.6 months. Seizure cause was drug toxicity in 8 patient
s (47%) and intracranial lesion in 6 patients (35.3%). Two patients had sei
zures related to metabolic derangements. No cause was found in 1 case. The
first seizure was generalized in 12 patients (70.6%), simple partial motor
seizure in 2 (11.8%), and simple partial seizure evolving to generalized se
izure in 3 (17.6%). We found partial seizures in 66.6% of patients who had
intracranial lesions. Most patients were treated with phenytoin, which was
well tolerated and effective in controlling seizures.
Conclusions: New-onset seizures are infrequent in patients with HIV. In mos
t cases a definite or probable cause is identified, which is usually relate
d to toxic and/or metabolic factors. Most seizures are generalized, and par
tial seizures suggest a focal cerebral lesion.